Long-acting inhaled beta(2)-agonist therapy in asthma.
Kips
J C
JC
Department of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium. johan.kips@rug.ac.be
Pauwels
R A
RA
D000287:Administration, Topical; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000328:Adult; D000367:Age Factors; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000730:Androstadienes / Q000008:administration & dosage; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001507:Beclomethasone / Q000008:administration & dosage; D001985:Bronchial Provocation Tests; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D019819:Budesonide / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage; D000068298:Fluticasone; D000068759:Formoterol Fumarate; D005938:Glucocorticoids; D006801:Humans; D015201:Meta-Analysis as Topic; D011110:Polymorphism, Genetic; D016032:Randomized Controlled Trials as Topic; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects* / Q000235:genetics; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000235:genetics; D012138:Respiratory Therapy; D000068299:Salmeterol Xinafoate; D013997:Time Factors
D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D004983:Ethanolamines; D005938:Glucocorticoids; D018343:Receptors, Adrenergic, beta-2; D011965:Receptors, Glucocorticoid; D019819:Budesonide; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D001507:Beclomethasone; D000420:Albuterol; D000068759:Formoterol Fumarate